ACAD ACADIA Pharmaceuticals Inc.

37.19
+0  (0%)
Previous Close 37.13
Open 37.11
Price To book 8.69
Market Cap 4.52B
Shares 121,407,000
Volume 1,262,051
Short Ratio 8.88
Av. Daily Volume 2,540,660

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated November 2016.
Pimavanserin
Adjunctive treatment in patients with negative symptoms of schizophrenia
Phase 3 initiated November 2016.
Pimavanserin
Adjunctive treatment of schizophrenia
Phase 2 trial initiated October 2016.
Pimavanserin - SERENE
Alzheimer’s disease agitation
Approved April 29 2016
Pimavanserin
Parkinson’s disease psychosis (PDP)
Phase 2 top-line data released December 20, 2016. Primary endpoint met. Key secondary endpoint missed.
Pimavanserin
Alzheimer’s disease psychosis

Latest News

  1. ETFs with exposure to ACADIA Pharmaceuticals, Inc. : March 6, 2017
  2. ACADIA PHARMACEUTICALS INC Financials
  3. ACADIA Pharmaceuticals, Inc. :ACAD-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017
  4. Edited Transcript of ACAD earnings conference call or presentation 28-Feb-17 10:00pm GMT
  5. ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
  6. Acadia Beats Analysts Estimates
  7. ACADIA Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today
  8. 4:14 pm ACADIA Pharmaceuticals misses by $0.01, beats on revs
  9. ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
  10. Q4 2016 ACADIA Pharmaceuticals Inc Earnings Release - After Market Close
  11. ACADIA Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference on March 6, 2017
  12. Will Acadia Beat Estimates Again? Maybe.
  13. ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?
  14. ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017
  15. Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta
  16. Acadia Pharmaceuticals Surge Higher Is More Than M&A Rumors
  17. Price Bump From M&A Rumors Earns Acadia A Vetr Downgrade
  18. Caution: Acadia Pharmaceuticals Is Overvalued
  19. A Potential $20 Billion Indication? 2 Must-Have Biotechs Taking on Alzheimer's Disease
  20. The Market In 5 Minutes: One For The Thumb